OTCPK:MEDVF - Post by User
Post by
Sarb99on Aug 30, 2020 12:14am
922 Views
Post# 31476260
Questcap diverse approach going to pay off end of the Day
Questcap diverse approach going to pay off end of the Day - Rather than developing QuestCap own test kits, they form a partnership. Rather than asking labs to sell QuestCap testing kits, they opened their own covid-19 testing centres. QuestCap does not need to buy any building or invest on lab equipment or accessories. Buy as many testing kits as the needs and can sell. Setup mobile testing centres in the pharmacy, schools, Shopping centres, stadiums, or any other place where they can sell. If one place does not get needed crowd, then move somewhere else, place with demand.
- If Abbott Saliva test are cheap, no problem, those tests should be done in a lab according to FDA approval. Start offering lab service for Abbott test. Then charge $25-$35 for lab service to offer Abbott $5 test. QuestCap still make same amount of money. QuestCap does not lose anything, start offering all kind of covid-19 testing. Lyher antibody, Abbott $5 test, Antigen test and take a cut. If they can sell $4 test in Columbia that mean they can compete with Abbott or anyone else.
- Spectral has already received Institutional Review Board (IRB) approval for the clinical study and the principal investigator for the first phase 1 clinical study has been initiated. Once Spectral receives approval to treat under the PIND application it will begin enrolment for the human clinical study immediately.
- Amino Therapeutics is currently focused on developing biologic therapeutics for COVID-19. Amino’s research targets small molecule drug candidates and targeted drug delivery systems to transport biologics into the cytosol.
- QuestCap invested in Glenco Medical Corp for long term revenue. QuestCap invested for 28% interest in Columbian Medical clinical, short term as they are busy doing covid-19 testing and long-term planning to open 3 more medical service centres.